Details
November 14 @ 11:45 am — 1:15 pm ET
Gaylord National Harbor, Riverview Ballroom B
This symposium is sponsored by The France Foundation and the American Association of Immunologists
Supported by: an educational grant from Novo Nordisk.
Speakers
Presenter
Dan Bessesen, MD, FTOS
University of Colorado Anschutz
Endocrinology/Metabolism/Diabetes
Professor of Medicine, Director of the Anschutz Health and Wellness Center
Aurora, CO
Presenter
Emily Goldberg, MD
University of California, San Francisco
Assistant Professor of Physiology
San Francisco, CA
Presenter
W. Timothy Garvey, MD, MACE, FTOS
University of Alabama at Birmingham
Charles E. Butterworth, Jr., Professor and University Professor
UAB Diabetes Research Center
Founding PI and Associate Director
Birmingham, AL
Presenter
Priya Jaisinghani, MD
NYU Langone Medical Associates—Penn District
Endocrinology and Obesity Medicine
Clinical Assistant Professor
New York, NY
Program Description
Join us for an engaging lunch symposium exploring the inflammatory processes underlying obesity and their implications for treatment. Faculty will examine the role of adipose tissue dysfunction and chronic inflammation in obesity, along with the effects of current obesity medications on weight, comorbidities, and inflammation.
The program will also explore amylin physiology and its relationship to obesity, with a focus on emerging amylin-based therapies, including amylin receptor agonists and GLP-1/amylin co-agonists. Faculty will discuss the latest evidence, areas of uncertainty, and how these approaches may shape the future of obesity care.
Led by a multidisciplinary panel of experts, this 90-minute symposium will connect the underlying science of obesity with current and emerging treatment strategies, offering insights clinicians can apply as the therapeutic landscape continues to evolve.
During this symposium, you will learn to:
- Describe obesity as a chronic, progressive disease characterized by adipose tissue dysfunction and chronic low-grade inflammation, which together contribute to metabolic complications
- Recognize the effects of current obesity medications on obesity-related inflammation and comorbidities
- Describe how amylin physiology relates to obesity
- Analyze the potential role of amylin-based therapies in future obesity treatment
Earn free CME!
Lunch will be served.
Register today!